Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Pre-close Trading Statement

23 Jan 2013 07:00

RNS Number : 1409W
Biome Technologies PLC
23 January 2013
 



23 January 2013

 

Biome Technologies plc

 

("Biome" or "the Group")

 

Pre-close Trading Statement

 

Biome Technologies plc, the bioplastics and RF technology business, is pleased to provide a pre-close trading statement for the financial year ended 31 December 2012 ahead of the announcement of the audited Preliminary Results, which are scheduled to be published on 27 March 2013.

 

The Board reports that it expects the financial performance of Biome for the full year period to be in line with its expectations. As announced in the Group's most recent trading update, following the sale of its 50% share in Biotec Holding GmbH ("Biotec") in October 2012 for £5.2m, the Board is assessing various options to accelerate the development strategy of the Group and expects to provide a fuller update at the Preliminary Results.

 

Following the successful sale of Biotec, Biome is now able to focus on the commercialisation and development of its 100% owned intellectual property in the area of premium products. Biome began this work in 2008 and is now involved with a number of interesting customer opportunities with significant market potential. These include the pre-launch evaluation work with a leading manufacturer of high performance single-use foodservice products and the launch of multi-layer sealing film for single-use coffee capsules. The former project is progressing well and the latter was market tested in the fourth quarter of 2012 with a full launch now underway in January 2013 with some 40 tonnes delivered already. While the expected growth trajectories of both of these applications are potentially strong, their actual performance will be clearer by the second half of 2013.

 

Biome is also investigating opportunities for the manufacture of bio-based materials through the use of synthetic biology. This is an emerging technology and Biome has a small number of early stage collaborations with both academic and industrial partners. The UK Government has identified the commercialisation of synthetic biology as an area of high priority where the UK can build a world leading position. The Board is exploring opportunities to accelerate the position of the business in this area in 2013 using mainly its intellectual, rather than its cash assets. To further this objective the business has an application for funding under consideration by the Technology Strategy Board (a Government body charged with making the UK a global leader in innovation) to support its research in this field.

 

The Stanelco RF Technologies team continues to explore opportunities to accelerate the expansion of the division and has a developing order book for the first half of 2013. This follows a slightly subdued end to 2012 as a number of optical fibre furnace deliveries were delayed due to some turbulence in the Chinese fibre market. Good progress continues on the Durapipe project and delivery timing for ten pre-production units is being finalised. The business has recently been appointed as the UK sales and service agent for Forsstrom High Frequency AB ("Forsstrom"). Forsstrom is a world leading supplier of High Frequency welding equipment and this agreement extends Stanelco's product offering into larger welding equipment.

 

The Group continues to challenge all aspects of its cost base. The legacy long leases on buildings in Southampton remain a significant drag on the path towards profitability and the Board is exploring a number of strategies that might mitigate this outflow.

 

As outlined previously, the Board is giving consideration to returning funds from the sale of Biotec to shareholders that may be in excess of those required in the medium term. As this would require a re-organisation of capital, given the large accumulated losses and substantial share premium accounts, the Board is examining all the issues relevant to that and expects to update shareholders at the Preliminary results.

 

The Group's existing debt facility has remained unutilised for some time. Given current cash balances and working capital needs, this facility was terminated on 22 January and will result in modest future cost savings. The Group's cash position at 31 December 2012 was up significantly to £6.3m (UK cash position 30 September 2012: £1.3m).

 

-Ends-

 

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com Tel: +44 (0) 2380 867 100

 

 

Daniel Stewart & Company plc

David Hart

www.danielstewart.co.uk Tel: +44 (0) 20 7776 6550

 

First Columbus

Chris Crawford/Kelly Gardiner

www.first-columbus.com Tel: +44 (0) 20 3002 2070

 

 

FTI Consulting

Oliver Winters/Latika Shah Tel: +44 (0) 20 7831 3113

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTVLLFLXFFXBBD
Date   Source Headline
27th Mar 20192:05 pmRNSSecond Price Monitoring Extn
27th Mar 20192:00 pmRNSPrice Monitoring Extension
13th Mar 20191:54 pmRNSHoldings in Company
24th Jan 20197:00 amRNSPre-close Trading Statement
31st Dec 20187:00 amRNSTotal Voting Rights
10th Dec 20182:35 pmRNS2017 Long Term Incentive Plan - First Vesting
6th Dec 20187:00 amRNSGrant funding from Innovate UK
23rd Nov 201812:38 pmRNSBiome to present at Mello London
1st Nov 20187:00 amRNSTrading update
3rd Sep 20187:00 amRNSInterim Results
23rd Jul 20187:00 amRNSTrading Update
31st May 20185:00 pmRNSTotal Voting Rights
2nd May 20184:13 pmRNSIssue of shares to directors & PDMR shareholdings
2nd May 20183:27 pmRNSProposed issue of shares to directors and dealings
24th Apr 201810:40 amRNSResult of Annual General Meeting
24th Apr 20187:00 amRNSTrading update
28th Mar 20181:52 pmRNSNotice of AGM and Annual Report and Accounts
27th Mar 20187:00 amRNSPreliminary Results
19th Feb 20182:05 pmRNSSecond Price Monitoring Extn
19th Feb 20182:00 pmRNSPrice Monitoring Extension
25th Jan 20187:00 amRNSPre-close Trading Statement
21st Dec 20177:00 amRNSNew LTIP and option grant
1st Nov 20177:00 amRNSTrading Update
4th Sep 20177:00 amRNSHalf-year Report
26th Jul 20179:30 amRNSDirector/PDMR Shareholding
25th Jul 20174:50 pmRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSTrading Update
24th Apr 201710:45 amRNSResult of AGM
24th Apr 20177:00 amRNSTrading Update
31st Mar 20172:50 pmRNSNotice of AGM and Annual Report and Accounts
29th Mar 20177:00 amRNSPreliminary Results
20th Jan 20177:00 amRNSPre-close Trading Statement
18th Jan 20177:00 amRNSSettlement Agreement
2nd Nov 20167:00 amRNSTrading Update
31st Aug 20167:00 amRNSHalf-year Report
27th Jun 20167:00 amRNSTrading Update
25th Apr 201612:34 pmRNSResult of Annual General Meeting
25th Apr 20167:00 amRNSTrading Update
1st Apr 201610:42 amRNSNotice of AGM and Annual Report and Accounts
30th Mar 20167:00 amRNSFinal Results
26th Jan 20167:00 amRNSPre-close Trading Statement
3rd Nov 20157:00 amRNSTrading Statement
2nd Sep 20157:00 amRNSInterim Results
23rd Jul 20157:00 amRNSTrading Update
19th Jun 20159:00 amRNSNew Contract
27th Apr 20154:46 pmRNSResult of AGM
27th Apr 20157:00 amRNSTrading Update
27th Mar 20153:43 pmRNSNotice of Annual General Meeting
25th Mar 20157:00 amRNSPreliminary Results
19th Feb 20153:26 pmRNSFunding Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.